BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le Clech A, Simon-tillaux N, Provôt F, Delmas Y, Vieira-martins P, Limou S, Halimi J, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-chiche N, Rondeau E, Frémeaux-bacchi V, Fakhouri F. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney International 2019;95:1443-52. [DOI: 10.1016/j.kint.2019.01.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Fakhouri F, Frémeaux-Bacchi V. Monitoring Complement Activation: The New Conundrum in Thrombotic Microangiopathies. Clin J Am Soc Nephrol 2019;14:1682-3. [PMID: 31811084 DOI: 10.2215/CJN.12111019] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Timmermans SAMEG, Damoiseaux JGMC, Werion A, Reutelingsperger CP, Morelle J, van Paassen P. Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes. Kidney Int Rep 2021;6:1099-109. [PMID: 33912760 DOI: 10.1016/j.ekir.2021.01.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Reference Citation Analysis]
4 Sánchez-Moreno A, de la Cerda F, Rodríguez-Barba A, Fijo J, Bedoya R, Arjona E, de Córdoba SR. Is the atypical hemolytic uremic syndrome risk polymorphism in Membrane Cofactor Protein MCPggaac relevant in kidney transplantation? A case report. Pediatr Transplant 2021;25:e13903. [PMID: 33217135 DOI: 10.1111/petr.13903] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Aigner C, Gaggl M, Kain R, Prohászka Z, Garam N, Csuka D, Sunder-Plassmann R, Piggott LC, Haninger-Vacariu N, Schmidt A, Sunder-Plassmann G. Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy. J Clin Med 2020;9:E964. [PMID: 32244370 DOI: 10.3390/jcm9040964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Park S, Lee YJ, Kim YW, Ko J, Park JH, Kim IH, Kim HJ, Oh D, Park BS. Atypical Hemolytic Uremic Syndrome (p.Gly1110Ala) with Autoimmune Disease. Am J Case Rep 2020;21:e922567. [PMID: 32361709 DOI: 10.12659/AJCR.922567] [Reference Citation Analysis]
7 Caravaca-Fontan F, Praga M. Complement inhibitors are useful in secondary hemolytic uremic syndromes. Kidney Int 2019;96:826-9. [PMID: 31543153 DOI: 10.1016/j.kint.2019.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C. [Acute kidney injury following acute pancreatitis (AP-AKI): Definition, Pathophysiology, Diagnosis and Therapy]. Z Gastroenterol 2020;58:1241-66. [PMID: 33291178 DOI: 10.1055/a-1255-3413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Timmermans SAMEG, van Paassen P. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J Clin Med 2021;10:3034. [PMID: 34300201 DOI: 10.3390/jcm10143034] [Reference Citation Analysis]
11 Werion A, Rondeau E. C5 Inhibition in Secondary Thrombotic Microangiopathies: A Yet Unresolved Question. Kidney Int Rep 2021;6:878-80. [PMID: 33939775 DOI: 10.1016/j.ekir.2021.02.012] [Reference Citation Analysis]
12 Caroti L, Cestone G, Di Maria L, Allinovi M, Li Marzi V, Serni S, Cirami CL. Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report. Clin Nephrol Case Stud 2021;9:59-66. [PMID: 34084691 DOI: 10.5414/CNCS110434] [Reference Citation Analysis]
13 Veríssimo R, Mateus C, Laranjinha I, Manso RT, Dickson J, Gonçalves M, Gaspar MA, Machado D. Thrombotic microangiopathy triggered by podocytopathy. Clin Nephrol Case Stud 2021;9:110-6. [PMID: 34646728 DOI: 10.5414/CNCS110534] [Reference Citation Analysis]
14 Portoles J, Huerta A, Arjona E, Gavela E, Agüera M, Jiménez C, Cavero T, Marrero D, Rodríguez de Córdoba S, Diekmann F; Matrix Investigators . Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J 2021;14:1173-80. [PMID: 33841863 DOI: 10.1093/ckj/sfaa096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Gómez Delgado I, Corvillo F, Nozal P, Arjona E, Madrid Á, Melgosa M, Bravo J, Szilágyi Á, Csuka D, Veszeli N, Prohászka Z, Sánchez-Corral P. Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome. Front Immunol 2021;12:641656. [PMID: 33777036 DOI: 10.3389/fimmu.2021.641656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Duineveld C, Wetzels JFM. Complement inhibitors are not useful in secondary hemolytic uremic syndromes. Kidney Int 2019;96:829-33. [PMID: 31543154 DOI: 10.1016/j.kint.2019.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Menne J. Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)? Kidney Int 2020;97:1106-8. [PMID: 32444092 DOI: 10.1016/j.kint.2020.03.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Bernuy-Guevara C, Chehade H, Muller YD, Vionnet J, Cachat F, Guzzo G, Ochoa-Sangrador C, Álvarez FJ, Teta D, Martín-García D, Adler M, de Paz FJ, Lizaraso-Soto F, Pascual M, Herrera-Gómez F. The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies. Biomedicines 2020;8:E355. [PMID: 32948059 DOI: 10.3390/biomedicines8090355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Palma LMP, Eick RG, Dantas GC, Tino MKDS, de Holanda MI; Brazilian Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome Study Group (aHUS Brazil). Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J 2021;14:1126-35. [PMID: 33841858 DOI: 10.1093/ckj/sfaa062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Patriquin CJ, Pavenski K, Garland J, Girard L, Isenring P. Complement-Amplifying Conditions in Atypical Hemolytic Uremic Syndrome: A Canadian Case Series. Can J Kidney Health Dis 2022;9:205435812211002. [DOI: 10.1177/20543581221100288] [Reference Citation Analysis]
22 Ronco P. Pathophysiology of the glomerulus: KI tells the story. Kidney Int 2020;97:5-9. [PMID: 31901357 DOI: 10.1016/j.kint.2019.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Sandino-Pérez J, Gutiérrez E, Caravaca-Fontán F, Morales E, Aubert-Girbal L, Delgado-Lillo R, Praga M. Haemolytic uraemic syndrome associated with pancreatitis: report of four cases and review of the literature. Clin Kidney J 2021;14:1946-52. [PMID: 34345418 DOI: 10.1093/ckj/sfaa245] [Reference Citation Analysis]
24 Timmermans SAMEG, Wérion A, Damoiseaux JGMC, Morelle J, Reutelingsperger CP, van Paassen P. Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy. Hypertension 2020;75:422-30. [PMID: 31865800 DOI: 10.1161/HYPERTENSIONAHA.119.13714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
25 Perrier Q, Noble J, Grangé S, Bedouch P, Tetaz R, Rostaing L. Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies. Case Rep Oncol 2021;14:676-80. [PMID: 33976652 DOI: 10.1159/000514982] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fakhouri F, Scully M, Provôt F, Blasco M, Coppo P, Noris M, Paizis K, Kavanagh D, Pène F, Quezada S, Hertig A, Kissling S, O'Brien P, Delmas Y, Alberio L, Winer N, Veyradier A, Cataland S, Frémeaux-Bacchi V, Loirat C, Remuzzi G, Tsatsaris V. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood 2020;136:2103-17. [PMID: 32808006 DOI: 10.1182/blood.2020005221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
27 Bahougne T, Olagne J, Munch M, Braun-Parvez L, Chenard MP, Frémeaux-Bacchi V, Caillard S, Baltzinger P, Greget M, Kessler L, Moulin B. Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report. BMC Nephrol 2020;21:405. [PMID: 32950058 DOI: 10.1186/s12882-020-02062-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Timmermans SA, Werion A, Morelle J, van Paassen P. Defects in complement and “secondary” hemolytic uremic syndrome. Kidney International 2019;96:517. [DOI: 10.1016/j.kint.2019.04.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
29 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Reference Citation Analysis]
30 Soraru J, Isbel N, Wong G, Coates PT, Mantha M, Abraham A, Juneja R, Hsu D, Brown F, Bose B, Mudge D, Carroll R, Kausman J, Hughes P, Barbour T, Durkan A, Mount P, Lee D, Larkins N, Ranganathan D, Lim WH. Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. Nephrology (Carlton) 2020;25:683-90. [PMID: 32378251 DOI: 10.1111/nep.13722] [Reference Citation Analysis]
31 Filippone EJ, Newman ED, Li L, Gulati R, Farber JL. Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review. Front Immunol 2021;12:780107. [PMID: 34858436 DOI: 10.3389/fimmu.2021.780107] [Reference Citation Analysis]
32 Grall M, Daviet F, Chiche NJ, Provot F, Presne C, Coindre JP, Pouteil-Noble C, Karras A, Guerrot D, François A, Benhamou Y, Veyradier A, Frémeaux-Bacchi V, Coppo P, Grangé S. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrol 2021;22:267. [PMID: 34284729 DOI: 10.1186/s12882-021-02470-3] [Reference Citation Analysis]
33 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Kim MJ, Lee H, Kim YH, Jin SY, Kim HJ, Oh D, Jeon JS. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report. BMC Nephrol 2021;22:86. [PMID: 33691638 DOI: 10.1186/s12882-021-02293-2] [Reference Citation Analysis]
35 Tavasoli A, Zafaranloo N, Hoseini R, Otukesh H, Nakhaiee S. Frequency of neurological involvement in patients with/without diarrhea hemolytic uremic syndrome: A Systematic review and meta-analysis. Med J Islam Repub Iran 2021;35:91. [PMID: 34956937 DOI: 10.47176/mjiri.35.91] [Reference Citation Analysis]
36 Haydock L, Garneau AP, Tremblay L, Yen HY, Gao H, Harrisson R, Isenring P. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. J Mol Med (Berl) 2021. [PMID: 34714369 DOI: 10.1007/s00109-021-02102-1] [Reference Citation Analysis]
37 Castelli R, Lambertenghi Delilliers G, Gidaro A, Cicardi M, Bergamaschini L. Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course. Clin Exp Immunol 2020;201:258-65. [PMID: 32515487 DOI: 10.1111/cei.13475] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
38 Praga M, Rodríguez de Córdoba S. Secondary atypical hemolytic uremic syndromes in the era of complement blockade. Kidney Int 2019;95:1298-300. [PMID: 31122707 DOI: 10.1016/j.kint.2019.01.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Gouin A, Ribes D, Colombat M, Chauveau D, Prevot G, Lairez O, Pugnet G, Fremeaux-Bacchi V, Huart A, Belliere J, Faguer S. Role of C5 inhibition in Idiopathic Inflammatory Myopathies and Scleroderma Renal Crisis-Induced Thrombotic Microangiopathies. Kidney Int Rep 2021;6:1015-21. [PMID: 33912751 DOI: 10.1016/j.ekir.2021.01.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]